Skip to content
researcher

Bishwa Tuladhar

Senior Lecturer in Pharmacology

Faculty/Dept/School School of Pharmacy and Medical Sciences
(Faculty of Life Sciences)
Emailb.r.tuladhar@bradford.ac.uk
Telephone +441274 234673

Research

My area of research interest is in gastrointestinal motility and emesis. In the gastrointestinal motility research, I have established many in-vitro techniques. I have developed probably the best model to study highly complex and extremely useful peristaltic reflex in many species including guinea -pigs and mice and in various gastrointestinal regions including the ileum and colon. In the emesis side, our focus had been on developing new antiemetic therapy. We have investigated neurokinin and various other agents in collaboration with different pharmaceutical industries. Another area of expertise in the emesis research had been in the dissociation of emetic potential from the developmental novel compounds. We have worked to dissociate emetic potential from developmental compounds such as PD4 inhibitors with industrial collaborations. My area of research interest is in gastrointestinal motility and emesis. In the gastrointestinal motility research, I have established many in-vitro techniques. I have developed probably the best model to study highly complex and extremely useful peristaltic reflex in many species including guinea -pigs and mice and in various gastrointestinal regions including the ileum and colon. In the emesis side, our focus had been on developing new antiemetic therapy. We have investigated neurokinin and various other agents in collaboration with different pharmaceutical industries. Another area of expertise in the emesis research had been in the dissociation of emetic potential from the developmental novel compounds. We have worked to dissociate emetic potential from developmental compounds such as PD4 inhibitors with industrial collaborations. My area of research interest is in gastrointestinal motility and emesis. In the gastrointestinal motility research, I have established many in-vitro techniques. I have developed probably the best model to study highly complex and extremely useful peristaltic reflex in many species including guinea -pigs and mice and in various gastrointestinal regions including the ileum and colon. In the emesis side, our focus had been on developing new antiemetic therapy. We have investigated neurokinin and various other agents in collaboration with different pharmaceutical industries. Another area of expertise in the emesis research had been in the dissociation of emetic potential from the developmental novel compounds. We have worked to dissociate emetic potential from developmental compounds such as PD4 inhibitors with industrial collaborations. Current Projects Development of in vitro peristalsis model Current Projects Development of in vitro peristalsis model Current Projects Development of in vitro peristalsis model Research Collaborations SK Life Sciences, New Jersey, USA (£5198.00; 2013) SK Life Sciences, New Jersey, USA Consultancy SK Life Sciences, New Jersey, USA (£27,812.00; 2009) SK Life Sciences, New Jersey, USA (£27,812.00; 2009) Investigation of the prokinetic effect of 5-HT4 receptor ligand BBSRC Case Studentship with GSK (£81,000; 2004). Modulation of peristalsis by endogenous mediators GSK, UK (£21,555; 2004) Comparison of abilities of alvimopam GSK, UK (£73,966; 2001) Enteric Nerve Reflex Functions in Mouse Gastrointestinal Tract Laboratories Dr. Esteeve, SPAIN (£7400, 2004, with Prof. Naylor) 5-HT7 receptors and GI activity Arakis Ltd, UK (£55600, 2002, with Prof. Naylor) Investigation of potentiation of antiemetic effect with selective isomers Arakis Ltd, UK (£51816, 2002, with Prof. Naylor) Testing of differential effect of isomers on emesis in the ferrets Arakis Ltd, UK (£28426, 2001, with Prof. Naylor) Testing Arakis compounds to antagonize drug induced emesis in the ferret model Novartis Horsham Research Centre, UK (£42887, 2001, with Prof. Naylor) Testing of Novartis PDE4 inhibitors HoffMann La Roche, Basel, Switzerland (£34652, 2001, with Prof. Naylor) Evaluation of the antiemetic effect of test compounds Merck Sharp & Dohme, UK (£27708, 2000, wiResearch Collaborations SK Life Sciences, New Jersey, USA (£5198.00; 2013) SK Life Sciences, New Jersey, USA Consultancy SK Life Sciences, New Jersey, USA (£27,812.00; 2009) SK Life Sciences, New Jersey, USA (£27,812.00; 2009) Investigation of the prokinetic effect of 5-HT4 receptor ligand BBSRC Case Studentship with GSK (£81,000; 2004). Modulation of peristalsis by endogenous mediators GSK, UK (£21,555; 2004) Comparison of abilities of alvimopam GSK, UK (£73,966; 2001) Enteric Nerve Reflex Functions in Mouse Gastrointestinal Tract Laboratories Dr. Esteeve, SPAIN (£7400, 2004, with Prof. Naylor) 5-HT7 receptors and GI activity Arakis Ltd, UK (£55600, 2002, with Prof. Naylor) Investigation of potentiation of antiemetic effect with selective isomers Arakis Ltd, UK (£51816, 2002, with Prof. Naylor) Testing of differential effect of isomers on emesis in the ferrets Arakis Ltd, UK (£28426, 2001, with Prof. Naylor) Testing Arakis compounds to antagonize drug induced emesis in the ferret model Novartis Horsham Research Centre, UK (£42887, 2001, with Prof. Naylor) Testing of Novartis PDE4 inhibitors HoffMann La Roche, Basel, Switzerland (£34652, 2001, with Prof. Naylor) Evaluation of the antiemetic effect of test compounds Merck Sharp & Dohme, UK (£27708, 2000, with Prof. Naylor) Examination of the antiemtic effects of test compounds Shering-Plough Research Institute, New Jersey, USA (£88268, 2000, with Prof. Naylor) Compounds as an antiemetic agent in ferrets SmithKline Beecham, UK (£12218, 1999, with Prof. Naylor) Ferret Model of Emesis Novartis Horsham Research Centre, UK (£26282, 1999, with Prof. Naylor) Emetic Potential of 4 Test compounds HoffMann La Roche, Basel, Switzerland (£115085, 1999, with Prof. Naylor) Emesis experiments to examine antiemetic effect of Roche compounds Cell Tech R & D Ltd, UK (£159125, 1999, with Prof. Naylor) Investigation of Tramadol Enantiomers Zambon Group, Italy (£50394, 1998) Research on Phosphodiesterase inhibitors Parke-Davis Neuroscience Research Centre, UK (£11081, 1997, with Prof. Naylor) Neurokinin antagonists as antiemetics Sandoz Institute for Medical Research, UK (£17209, 1995, with Prof. Naylor) Investigation of role of neurokinins Parke-Davis Neuroscience Research Centre, UK (£34835, 1995, with Prof. Naylor) Neurokinin antagonists as antiemetic agents Parke-Davis Neuroscience Research Centre, UK (£8165, 1995, with Prof. Naylor) Investigation of a peripheral treatment Parke-Davis Neuroscience Research Centre, UK (£38415, 1995, with Prof. Naylor) Anti-emtic activity of CGP A & CGP B Cell Tech R & D Ltd, UK (£405512, 1995, with Prof. Naylor) Study on CHI066 Short term Contract Parke-Davis Neuroscience Research Centre, UK (£7351, 1995, with Prof. Naylor) Investigation of the peripheral administration